Ana Livun1, Kate J Newberry2, Taghi Manshouri2, Rajko Kusec3, Srdan Verstovsek4. 1. Division of Molecular Diagnostics and Genetics, Department of Laboratory Diagnosis, Dubrava University Hospital, Zagreb, Croatia. 2. Department of Leukemia, The University of MD Anderson Cancer Center, Houston, TX, U.S.A. 3. University of Zagreb, School of Medicine, Zagreb, Croatia. 4. Department of Leukemia, The University of MD Anderson Cancer Center, Houston, TX, U.S.A. sverstov@mdanderson.org.
Abstract
AIM: The purpose of the present study was to determine whether genes involved in the organization of the hematopoietic niche were dysregulated in patients with primary myelofibrosis (MF) treated with lenalidomide. MATERIALS AND METHODS: We used reverse-transcription quantitative polymerase chain reaction to study the expression of a set of genes involved in the organization of the hematopoietic niche in peripheral blood and bone marrow (BM) mononuclear cell (MNC) samples from 32 patients with primary MF who participated in a phase II trial of lenalidomide plus prednisone. RESULTS: At baseline (before treatment) cyclo-oxygenase 2 (COX2) was significantly up-regulated, while chemokine (C-X-C motif) receptor 4 (CXCR4), paired box 5 (PAX5) C-terminus, and hypoxia inducible factor 1A (HIF1A) were significantly down-regulated in BM MNCs from patients with primary MF compared to BM MNCs from healthy individuals. After 9 months of treatment, the expression of suppressor of cytokine signaling 3 (SOCS3) was significantly increased. CONCLUSION: Patients with primary MF showed aberrant expression of several genes involved in maintaining BM homeostasis and our findings suggest that treatment with lenalidomide plus prednisone up-regulates SOCS3. Copyright
AIM: The purpose of the present study was to determine whether genes involved in the organization of the hematopoietic niche were dysregulated in patients with primary myelofibrosis (MF) treated with lenalidomide. MATERIALS AND METHODS: We used reverse-transcription quantitative polymerase chain reaction to study the expression of a set of genes involved in the organization of the hematopoietic niche in peripheral blood and bone marrow (BM) mononuclear cell (MNC) samples from 32 patients with primary MF who participated in a phase II trial of lenalidomide plus prednisone. RESULTS: At baseline (before treatment) cyclo-oxygenase 2 (COX2) was significantly up-regulated, while chemokine (C-X-C motif) receptor 4 (CXCR4), paired box 5 (PAX5) C-terminus, and hypoxia inducible factor 1A (HIF1A) were significantly down-regulated in BM MNCs from patients with primary MF compared to BM MNCs from healthy individuals. After 9 months of treatment, the expression of suppressor of cytokine signaling 3 (SOCS3) was significantly increased. CONCLUSION:Patients with primary MF showed aberrant expression of several genes involved in maintaining BM homeostasis and our findings suggest that treatment with lenalidomide plus prednisone up-regulates SOCS3. Copyright
Authors: Nasios Fourouclas; Juan Li; Daniel C Gilby; Peter J Campbell; Philip A Beer; Elaine M Boyd; Anne C Goodeve; David Bareford; Claire N Harrison; John T Reilly; Anthony R Green; Anthony J Bench Journal: Haematologica Date: 2008-09-24 Impact factor: 9.941
Authors: Cesar Cilento Ponce; Maria de Lourdes Lopes Ferrari Chauffaille; Silvia Saiuli Miki Ihara; Maria Regina Regis Silva Journal: Rev Bras Hematol Hemoter Date: 2014-07-18